Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma
- PMID: 8691844
- DOI: 10.1002/(SICI)1096-9098(199608)62:4<288::AID-JSO14>3.0.CO;2-1
Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma
Abstract
We characterized a new mammary tumor cell line, F3II, previously established in vitro from a clonal subpopulation of the BALB/c transplantable mammary adenocarcinoma M3, moderately metastatic to lung. The F3II cell line has been passaged > 50 times. It has grown as elongated cells adherent to the bottom of the flask. Cytogenetic studies showed that F3II cultures were nearly triploid. Tumor cells expressed fibronectin and showed high levels of cell-surface urokinase, a key protease in invasion and metastasis. F3II cells grew as poorly differentiated, spindle-cell carcinoma tumors (sarcomatoid carcinomas) with a prominent local invasiveness, a high angiogenic response, and a 90-100% incidence of lung metastases when inoculated s.c. into syngeneic mice. Ultrastructural and immunocytochemical analysis revealed characteristic features of carcinomas. Our data suggest that F3II is less differentiated and more aggressive than the original tumor line, supporting the notion that mammary carcinomas are heterogeneous neoplasms and contain subpopulations with diverse biologic behavior. The F3II mouse mammary sarcomatoid carcinoma line is a suitable model to examine antiinvasive, antiangiogenic, and antimetastatic agents.
Similar articles
-
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.J Natl Cancer Inst. 2006 Jun 7;98(11):756-64. doi: 10.1093/jnci/djj208. J Natl Cancer Inst. 2006. PMID: 16757700
-
Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.Oncol Rep. 1998 Jan-Feb;5(1):209-12. Oncol Rep. 1998. PMID: 9458324
-
Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.Oncol Rep. 2003 May-Jun;10(3):725-32. Oncol Rep. 2003. PMID: 12684650
-
Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428.Anticancer Res. 1998 Nov-Dec;18(6A):4499-504. Anticancer Res. 1998. PMID: 9891516
-
Carcinosarcomas: current perspectives and an historical review of nosological concepts.Semin Diagn Pathol. 1993 May;10(2):118-27. Semin Diagn Pathol. 1993. PMID: 8367621 Review.
Cited by
-
Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice.J Breast Cancer. 2022 Jun;25(3):218-232. doi: 10.4048/jbc.2022.25.e18. Epub 2022 Apr 26. J Breast Cancer. 2022. PMID: 35657001 Free PMC article.
-
Efficacy of direct current generated by multiple-electrode arrays on F3II mammary carcinoma: experiment and mathematical modeling.J Transl Med. 2020 May 7;18(1):190. doi: 10.1186/s12967-020-02352-6. J Transl Med. 2020. PMID: 32381006 Free PMC article.
-
TGF-β2 dictates disseminated tumour cell fate in target organs through TGF-β-RIII and p38α/β signalling.Nat Cell Biol. 2013 Nov;15(11):1351-61. doi: 10.1038/ncb2861. Epub 2013 Oct 27. Nat Cell Biol. 2013. PMID: 24161934 Free PMC article.
-
Genistein-triggered anticancer activity against liver cancer cell line HepG2 involves ROS generation, mitochondrial apoptosis, G2/M cell cycle arrest and inhibition of cell migration.Arch Med Sci. 2019 Jul;15(4):1001-1009. doi: 10.5114/aoms.2018.78742. Epub 2018 Oct 3. Arch Med Sci. 2019. PMID: 31360194 Free PMC article.
-
Immunotherapy with SLPI over-expressing mammary tumor cells decreases tumor growth.Cancer Immunol Immunother. 2011 Jun;60(6):895-900. doi: 10.1007/s00262-011-1018-2. Epub 2011 Apr 26. Cancer Immunol Immunother. 2011. PMID: 21519828 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials